(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2014 (25.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/153052 A9

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *A61K 31/7105* (2006.01)

(21) **International Application Number**:
PCT/US2014/028849

(22) **International Filing Date**:
14 March 2014 (14.03.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/783,663 14 March 2013 (14.03.2013) US

(71) **Applicants**: **SHIRE HUMAN GENETIC THERAPIES, INC.** [US/US]; 300 Shire Way, Lexington, MA 02421 (US). **ETHRIS GMBH** [DE/DE]; Lochhamerstr. 11, 82152 Martinsried (DE).

(72) **Inventors**: **HEARTLEIN, Michael**; C/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **GUILD, Braydon, Charles**; 109 Riverdale Road, Concord, MA 01742 (US). **DEROSA, Frank**; C/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US). **RUDOLPH, Carsten**; C/o Ethris Gmbh, Lochhamerstr. 11, 82152 Martinsried (DE). **PLANK, Christian**; C/o Ethris Gmbh, Lochhamerstr. 11, 82152 Martinsried (DE). **SMITH, Lianne**; C/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, MA 02421 (US).

(74) **Agents**: **CHEN, Fangli** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, MA 02110 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(48) **Date of publication of this corrected version**:
6 August 2015

(15) **Information about Correction**:
see Notice of 6 August 2015

WO 2014/153052 A9

(54) **Title**: CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES

(57) **Abstract**: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.